Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?

Leming Shi, Benjamin Haibe-Kains, Nicolai Juul Birkbak, Philippe L. Bedard, Christos Hatzis, David F. Stern, Robert Clarke, John Quackenbush, Andrew H. Beck, Hugo J. W. L. Aerts

    Research output: Contribution to journalJournal articleResearchpeer-review

    Abstract

    Large-scale pharmacogenomic high-throughput screening (HTS) studies hold great potential for generating robust genomic predictors of drug response. Two recent large-scale HTS studies have reported results of such screens, revealing several known and novel drug sensitivities and biomarkers. Subsequent evaluation, however, found only moderate interlaboratory concordance in the drug response phenotypes, possibly due to differences in the experimental protocols used in the two studies. This highlights the need for community-wide implementation of standardized assays for measuring drug response phenotypes so that the full potential of HTS is realized. We suggest that the path forward is to establish best practices and standardization of the critical steps in these assays through a collective effort to ensure that the data produced from large-scale screens would not only be of high intrastudy consistency, so that they could be replicated and compared successfully across multiple laboratories.
    Original languageEnglish
    JournalCancer Research
    Volume74
    Issue number15
    Pages (from-to)4016-4023
    Number of pages8
    ISSN0008-5472
    DOIs
    Publication statusPublished - 2014

    Keywords

    • drug response phenotype
    • drug sensitivity
    • genome
    • Primates Mammalia Vertebrata Chordata Animalia (Animals, Chordates, Humans, Mammals, Primates, Vertebrates) - Hominidae [86215] human common
    • biomarker
    • 10062, Biochemistry studies - Nucleic acids, purines and pyrimidines
    • 12512, Pathology - Therapy
    • 22002, Pharmacology - General
    • 22005, Pharmacology - Clinical pharmacology
    • 24004, Neoplasms - Pathology, clinical aspects and systemic effects
    • cancer drug screening laboratory techniques
    • large-scale pharmacogenomic high-throughput screening laboratory techniques
    • Methods and Techniques
    • Pharmacology
    • Tumor Biology
    • ONCOLOGY
    • MICROARRAY DATA
    • CYTOTOXICITY
    • INHIBITION
    • DISCOVERY
    • SENSITIVITY
    • STANDARDS
    • MELANOMA
    • STRATEGY
    • IMPACT
    • TARGET
    • Reviews

    Fingerprint Dive into the research topics of 'Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?'. Together they form a unique fingerprint.

    Cite this